Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 41 Seyon Street, Bldg. 1, Suite 100 ...

Key Takeaways Repligen posted Q4 2025 EPS of 49 cents, beating estimates. Revenues rose 18% Y/Y to $198M.Repligen delivered 14% organic growth in Q4 2025, with Proteins and Process Analytics up over 30%.Repligen guides 2026 revenues of $810-$840M and estimates EPS to be in the band of $1.93-$2.01.Repligen Corporation (RGEN) reported fourth-quarter 2025 adjusted earnings per share of 49 cents, which came ahead of the Zacks Consensus Estimate and the year-ago adjusted earnings of 44 cents per share.Total reve ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - Vice President Equity ResearchDoug Schenkel - Managing Director, Life Science Tools, and DiagnosticsJacob Johnson - VP and Head of Investor RelationsJason Garland - CFOOlivier Loeillot - President and CEOPhilip Boyd - Senior Managing DirectorSubbu Nambi - Managing Director and Healthcare Equity ResearchNone - Company RepresentativeConference Call Participants ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - Vice President Equity ResearchDoug Schenkel - Managing Director, Life Science Tools, and DiagnosticsJacob Johnson - VP and Head of Investor RelationsJason Garland - CFOOlivier Loeillot - President and CEOPhilip Boyd - Senior Managing DirectorSubbu Nambi - Managing Director and Healthcare Equity ResearchNone - Company RepresentativeConference Call Participants ...

Repligen (NasdaqGS:RGEN) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker12I would now like to turn the conference over to Jacob Johnson, Vice President, Investor Relations. You may begin.Speaker5Thank you, operator, and welcome everyone to our 2025 fourth quarter report. On this call, we will cover business highlights and financial performance for the three and 12-month periods ended December 31st, 2025, and we'll provide financial guidance for the full year 2026. Joining us on the call today ar ...

Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance WALTHAM, Mass., February 24, 2026 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financ ...

Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year increase of 16% for both reported and organic non-COVIDFull year 2026 revenue guidance of $810 million - $840 million, 10% to 14% reported revenue growth, 9% to 13% organic and adjusted operating margin expansion of 150 bps at the midpoint WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporatio ...

What happened According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Brown Capital Management sold 232,073 shares of Manhattan Associates (NASDAQ:MANH) during the fourth quarter of 2025. The estimated transaction value was $42.42 million, based on the average closing price for the period. At quarter’s end, the position’s reported value fell by $53.51 million, reflecting both the share sale and stock price movement. What else to know The sale reduced the stake to 2.67% of rep ...

Core Viewpoint - Repligen Corporation will report its fourth quarter 2025 financial results on February 24, 2026, with a conference call scheduled for 8:30 a.m. ET to discuss the results and business updates [1]. Group 1: Financial Reporting - The financial results will cover the three- and twelve-month periods ending December 31, 2025 [1]. - A press release will be issued before the market opens on the reporting date [1]. Group 2: Conference Call Details - The conference call can be accessed by domestic callers at toll-free number (800) 715-9871 and international callers at (646) 307-1963, with no passcode required [2]. - A webcast of the conference call will be available on the Investor Relations section of the company's website, and both the call and webcast will be archived for later access [2]. Group 3: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for the manufacturing of biological drugs [3]. - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3]. - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3].

Company Overview - Repligen is headquartered in Waltham, Massachusetts and employs approximately 2,000 people [2][3] - The company focuses on bioprocessing and has dual manufacturing capabilities in the U.S. and Europe [3] Financial Guidance - For 2025, Repligen projects sales to reach USD 733 million at the midpoint of their guidance [3] Vision and Strategy - The company's vision is to be the global leader in bioprocessing innovation, offering a diverse portfolio of data-driven solutions across various therapeutic modalities [4] - Innovation has been a key focus for Repligen over the past decade, positioning the company in a large bioprocessing market with significant competition [5]